Home » Stocks » DXCM

DexCom, Inc. (DXCM)

Stock Price: $400.04 USD 0.55 (0.14%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $400.50 +0.46 (0.12%) Apr 16, 7:42 PM
Market Cap 38.69B
Revenue (ttm) 1.93B
Net Income (ttm) 493.60M
Shares Out 94.40M
EPS (ttm) 5.06
PE Ratio 79.06
Forward PE 169.49
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $400.04
Previous Close $399.49
Change ($) 0.55
Change (%) 0.14%
Day's Open 400.57
Day's Range 393.64 - 401.65
Day's Volume 550,050
52-Week Range 305.63 - 456.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distributi...

1 week ago - Business Wire

Will future Tyvaso revenue growth push United Therapeutics to new heights?

Other stocks mentioned: UTHR
2 weeks ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time.

2 weeks ago - Business Wire

Financial media can often divert your attention away from the best investments.

Other stocks mentioned: ALGN, RGEN
2 weeks ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)---- $DXCM--Dexcom Promotes Jereme Sylvain to Chief Financial Officer

3 weeks ago - Business Wire

Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.

Other stocks mentioned: ABT
1 month ago - Zacks Investment Research

Toxic stocks are vulnerable to external shocks and are burdened with huge debts. It's important to ensure that you safeguard your portfolio from such stocks.

Other stocks mentioned: CDAY, CWST, HXL
1 month ago - Zacks Investment Research

When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can hel...

Other stocks mentioned: BDX, MDT
1 month ago - 24/7 Wall Street

Lone Pine Capital, the hedge fund founded by Steve Mandel (Trades, Portfolio) in 1997, disclosed its fourth-quarter 2020 portfolio last week.

Other stocks mentioned: BILI, COF, CVNA, FB, PYPL, SNAP
1 month ago - GuruFocus

Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.

Other stocks mentioned: HXL, PAYC, RCM
1 month ago - Zacks Investment Research

DexCom Inc. (NASDAQ:DXCM) said it expects 2021 revenue to increase between 15% and 20% to more than $2.2 billion as it extends its diabetes care business into two new areas of the disease, prediabetes a...

2 months ago - GuruFocus

If the market plunges, picking up these fast-paced companies at a discount would be a wise move.

Other stocks mentioned: AMZN, CRWD, IIPR
2 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations

2 months ago - Business Wire

DexCom CEO says Super Bowl ad sparked high interest in its glucose tracker

YouTube video

DexCom CEO Kevin Sayer said the company had 5 times more media impressions in one day than it had all last year after airing Super Bowl spot featuring Nick Jonas, helping to get the message out about it...

2 months ago - CNBC Television

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

2 months ago - Zacks Investment Research

DexCom (DXCM) delivered earnings and revenue surprises of 0.00% and 1.88%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Dexcom Launches Inaugural Venture Capital Fund

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Fourth Quarter 2020 Financial Results

2 months ago - Business Wire

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

2 months ago - Zacks Investment Research

The stock price of DexCom, best known for its continuous glucose monitoring systems, has risen by 10% over the last five trading days. Earlier in January, the company reported strong preliminary numbers...

2 months ago - Forbes

Hint: Much of a company's success has to do with the experiences and diversity of its leadership.

Other stocks mentioned: AMWL, TDOC
2 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 11, 2021 at 4:30 p.m. Eastern Time.

2 months ago - Business Wire

The stock market's benchmark index is packed with big-time value.

Other stocks mentioned: AVGO, FB, MA
3 months ago - The Motley Fool

DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

3 months ago - Zacks Investment Research

Teladoc (TDOC) and Dexcom jointly provide solutions for patients with Type 2 diabetes, a common lifestyle-induced malady.

Other stocks mentioned: TDOC
3 months ago - Zacks Investment Research

These two providers of diabetes-related products and services have yet to scratch the surface of their potential.

Other stocks mentioned: TNDM
3 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook

3 months ago - Business Wire

DexCom (DXCM) closed the most recent trading day at $388.09, moving +0.24% from the previous trading session.

3 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference

3 months ago - Business Wire

These stocks can handle whatever the new year has in store.

Other stocks mentioned: REGN, VRTX
3 months ago - The Motley Fool

The highflying Nasdaq 100 is hiding some serious value in plain sight.

Other stocks mentioned: FB, VRTX
3 months ago - The Motley Fool

Businesses in these fast-growing trends can shine in a young bull market.

Other stocks mentioned: AMZN, GOOG, GOOGL, CRLBF, FRPT, GTBIF, TDOC ...
3 months ago - The Motley Fool

In the latest trading session, DexCom (DXCM) closed at $355.02, marking a -0.27% move from the previous day.

3 months ago - Zacks Investment Research

DexCom is an attractive company riding a long-term secular trend in the growth of chronic care management. Stock has performed well this year and is trading at the high range of historical averages.

3 months ago - Seeking Alpha

DexCom (DXCM) closed at $358.57 in the latest trading session, marking a +0.18% move from the prior day.

4 months ago - Zacks Investment Research

This healthcare technology company is disrupting the diabetes market with innovative technologies that patients love.

4 months ago - The Motley Fool

DexCom CEO: We're more bullish about the business than we've ever been

YouTube video

DexCom CEO Kevin Sayer reaffirms his long-term outlook for the diabetes management company, forecasting growth as high as 20% through 2025.

4 months ago - CNBC Television

Investors have a few questions as the company faces increasing competition.

4 months ago - The Motley Fool

These companies have growth opportunities that will last long after the COVID vaccine gets life back to normal.

Other stocks mentioned: BNTX, QDEL
4 months ago - The Motley Fool

These stocks could make you a fortune over the next decade.

Other stocks mentioned: DOCU, SHOP
4 months ago - The Motley Fool

Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.

Other stocks mentioned: PRAH, TDOC
4 months ago - Zacks Investment Research

Probably not, but it'll still beat the market.

4 months ago - The Motley Fool

Biotech stocks simply can't match these reliable returns.

Other stocks mentioned: MDT, ABMD
5 months ago - The Motley Fool

These two companies are battling for market share of continuous glucose monitoring devices for diabetes, with each coming out with new models soon.

Other stocks mentioned: ABT
5 months ago - The Motley Fool

G7 could change the valuation dramatically. It is a risky play, especially in the short term.

5 months ago - Seeking Alpha

Instead of investing in the company that would have made you a millionaire years ago, seek out the ones that have the potential from here.

Other stocks mentioned: EXAS
5 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations

5 months ago - Business Wire

These stocks have beaten the odds in 2020 and can weather future storms.

Other stocks mentioned: BDX, TDOC, UNH, VRTX
5 months ago - The Motley Fool

With the disruption that the coronavirus caused us, the dependency on tech-based solutions makes these IoT stocks very relevant. The post 7 IoT Stocks That Are Banking on a Connected Future appeared fir...

Other stocks mentioned: ALRM, CSCO, IBM, INTC, NVDA, NXPI
5 months ago - InvestorPlace

An analyst downgrade and marketwide turbulence weighed on the medical device maker's shares last month.

5 months ago - The Motley Fool

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LL... [Read more...]

Industry
Diagnostics & Research
IPO Date
Apr 14, 2005
CEO
Kevin Sayer
Employees
5,500
Stock Exchange
NASDAQ
Ticker Symbol
DXCM
Full Company Profile

Financial Performance

In 2020, DexCom's revenue was $1.93 billion, an increase of 30.54% compared to the previous year's $1.48 billion. Earnings were $493.60 million, an increase of 388.23%.

Financial Statements

Analyst Forecasts

According to 21 analysts, the average rating for DexCom stock is "Buy." The 12-month stock price forecast is 466.00, which is an increase of 16.49% from the latest price.

Price Target
$466.00
(16.49% upside)
Analyst Consensus: Buy